tmv-peptide vaccine

**tmv-peptide vaccine** refers to a class of candidate vaccines in which *short peptides* representing antigenic epitopes—often from pathogens such as SARS-CoV-2—are genetically fused or chemically conjugated to the coat protein of the **tobacco mosaic virus (TMV)**, a well-studied plant virus. The TMV nanoparticle serves as a *highly immunogenic carrier*, enhancing the peptide’s presentation to the immune system. These vaccines have been shown to elicit robust humoral (antibody-mediated) and cellular (T cell–mediated) immune responses in preclinical models, including strong IFN-γ secretion, dendritic cell activation, and virus-neutralizing antibody production. TMV-epitope fusions have particular stability across a range of temperatures and can be rapidly adapted for new or mutating pathogens or for use as personalized cancer vaccines. Mechanistically, the TMV nanoparticle acts as an *adjuvant*, promotes antigen uptake by dendritic cells, and presents the peptide antigen for immune recognition. TMV-peptide vaccines have been evaluated in mice for infectious diseases (notably COVID-19) and cancer, and have been developed for both injectable and microneedle delivery[1][2][3][5].

Other names

tobacco mosaic virus-peptide vaccineTMV-peptide fusion vaccineTMV-epitope display vaccine